WAVE Life Sciences Ltd (NAS:WVE)
$ 5.74 0.22 (3.99%) Market Cap: 716.00 Mil Enterprise Value: 590.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 63/100

WAVE Life Sciences Ltd to Discuss the FOCUS-C9 Clinical Trial Update Investor Call Transcript

Apr 04, 2022 / 12:30PM GMT
Release Date Price: $2.32 (+14.29%)
Operator

Good morning, and welcome to the Wave Life Sciences FOCUS-C9 Clinical Trial Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded and webcast.

I'll now turn the call over to Kate Rausch, Head of Investor Relations at Wave Life Sciences. Please go ahead.

Kate Rausch
Wave Life Sciences Ltd. - Head of IR

Thank you, operator. Good morning, and thank you for joining us today. This morning, we issued a news release providing an update on our FOCUS-C9 Clinical Trial. For those participating via conference call, we have made slides available via webcast. A replay of this call will also be available in the Investors section of our website following the call.

Joining me in the room today with prepared remarks are Dr. Paul Bolno, Wave's President and Chief Executive Officer; Dr. Mike Panzara, Chief Medical Officer, Head of Therapeutics Discovery and Development; and calling in from AAN in Seattle, Dr. Merit Cudkowicz, Chief of MGH Hospital, Neurology Service and Professor of Neurology at Harvard Medical School.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot